NASDAQ:CORV - Correvio Pharma Stock Price, News & Analysis

-0.07 (-2.88 %)
(As of 09/19/2019 04:00 PM ET)
Today's Range
Now: $2.36
50-Day Range
MA: $1.97
52-Week Range
Now: $2.36
Volume49,900 shs
Average Volume161,149 shs
Market Capitalization$119.19 million
P/E RatioN/A
Dividend YieldN/A
Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CORV



Sales & Book Value

Annual Sales$28.67 million
Book Value$0.19 per share


Net Income$-16,580,000.00
Net Margins-107.91%


Market Cap$119.19 million
Next Earnings Date11/5/2019 (Estimated)

Receive CORV News and Ratings via Email

Sign-up to receive the latest news and ratings for CORV and its competitors with MarketBeat's FREE daily newsletter.

Correvio Pharma (NASDAQ:CORV) Frequently Asked Questions

What is Correvio Pharma's stock symbol?

Correvio Pharma trades on the NASDAQ under the ticker symbol "CORV."

How were Correvio Pharma's earnings last quarter?

Correvio Pharma Corp (NASDAQ:CORV) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.05. The company earned $7.39 million during the quarter, compared to the consensus estimate of $7.64 million. Correvio Pharma had a negative net margin of 107.91% and a negative return on equity of 575.20%. View Correvio Pharma's Earnings History.

When is Correvio Pharma's next earnings date?

Correvio Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Correvio Pharma.

What price target have analysts set for CORV?

6 equities research analysts have issued 1-year price objectives for Correvio Pharma's shares. Their predictions range from $6.00 to $7.00. On average, they expect Correvio Pharma's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 186.0% from the stock's current price. View Analyst Price Targets for Correvio Pharma.

What is the consensus analysts' recommendation for Correvio Pharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Correvio Pharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Correvio Pharma.

Has Correvio Pharma been receiving favorable news coverage?

Media stories about CORV stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Correvio Pharma earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Correvio Pharma.

Are investors shorting Correvio Pharma?

Correvio Pharma saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 545,100 shares, an increase of 7.6% from the July 31st total of 506,400 shares. Based on an average trading volume of 135,500 shares, the days-to-cover ratio is presently 4.0 days. Currently, 2.1% of the company's shares are short sold. View Correvio Pharma's Current Options Chain.

Who are some of Correvio Pharma's key competitors?

What other stocks do shareholders of Correvio Pharma own?

Who are Correvio Pharma's key executives?

Correvio Pharma's management team includes the folowing people:
  • Mark H. N. Corrigan, Chief Executive Officer & Director
  • Justin A. Renz, President & Chief Financial Officer
  • Sheila M. Grant, Chief Operating Officer
  • Hugues Sachot, Chief Commercial Officer
  • David Dean, Chief Business Development Officer

Who are Correvio Pharma's major shareholders?

Correvio Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Westfield Capital Management Co. LP (9.55%), Tamarack Advisers LP (6.63%), Summer Road LLC (6.58%), Putnam Investments LLC (2.62%), Renaissance Technologies LLC (1.12%) and River & Mercantile Asset Management LLP (1.11%).

Which major investors are selling Correvio Pharma stock?

CORV stock was sold by a variety of institutional investors in the last quarter, including Summer Road LLC, Putnam Investments LLC and Renaissance Technologies LLC.

Which major investors are buying Correvio Pharma stock?

CORV stock was purchased by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, ARS Investment Partners LLC, LPL Financial LLC, Westfield Capital Management Co. LP and Commonwealth Equity Services LLC.

How do I buy shares of Correvio Pharma?

Shares of CORV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Correvio Pharma's stock price today?

One share of CORV stock can currently be purchased for approximately $2.36.

How big of a company is Correvio Pharma?

Correvio Pharma has a market capitalization of $119.19 million and generates $28.67 million in revenue each year. The company earns $-16,580,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Correvio Pharma employs 163 workers across the globe.View Additional Information About Correvio Pharma.

What is Correvio Pharma's official website?

The official website for Correvio Pharma is

How can I contact Correvio Pharma?

Correvio Pharma's mailing address is 1441 Creekside Drive 6th Floor, Vancouver A1, V6J 4S7. The company can be reached via phone at 604-677-6905 or via email at [email protected]

MarketBeat Community Rating for Correvio Pharma (NASDAQ CORV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about Correvio Pharma and other stocks. Vote "Outperform" if you believe CORV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel